Detalhe da pesquisa
1.
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med
; 387(24): 2220-2231, 2022 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36507690
2.
Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma.
Blood
; 141(18): 2187-2193, 2023 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36898085
3.
Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma.
Br J Haematol
; 204(2): 514-524, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37853658
4.
Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas.
Br J Haematol
; 204(1): 151-159, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37690811
5.
The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma.
Blood
; 140(4): 303-308, 2022 07 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35580172
6.
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study.
Haematologica
; 109(4): 1184-1193, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646659
7.
Deep learning and atlas-based models to streamline the segmentation workflow of total marrow and lymphoid irradiation.
Radiol Med
; 129(3): 515-523, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38308062
8.
Risk of Cancer in Inflammatory Bowel Diseases: Umbrella Review and Reanalysis of Meta-analyses.
Gastroenterology
; 163(3): 671-684, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35643170
9.
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
Blood
; 137(19): 2634-2645, 2021 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33211842
10.
A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma.
Hematol Oncol
; 41(1): 108-119, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36251503
11.
Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics.
Br J Haematol
; 198(1): 82-92, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35468225
12.
Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.
Haematologica
; 107(5): 1153-1162, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34289655
13.
Quality of life of adult cancer survivors enrolled in Humanitas Research Hospital's survivorship care model.
Support Care Cancer
; 30(7): 5561-5564, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35129665
14.
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
Lancet Oncol
; 22(6): 790-800, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33989558
15.
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma.
Invest New Drugs
; 39(4): 1028-1035, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33523334
16.
Expanded circulating hematopoietic stem/progenitor cells as novel cell source for the treatment of TCIRG1 osteopetrosis.
Haematologica
; 106(1): 74-86, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31949009
17.
Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi.
Ann Hematol
; 100(10): 2547-2556, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34327561
18.
Nonmyeloablative Conditioning Regimen before T Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Hodgkin and Non-Hodgkin Lymphomas.
Biol Blood Marrow Transplant
; 26(12): 2299-2305, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32822845
19.
Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade?
Blood
; 132(1): 17-22, 2018 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29716887
20.
Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma.
Blood
; 141(22): 2780-2783, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36898084